Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 1/2022

14.02.2022 | Macrovascular Complications in Diabetes (R Shah, Section Editor)

The Diabetes-Cardiovascular Connection in Women: Understanding the Known Risks, Outcomes, and Implications for Care

verfasst von: Eric K. Broni, Chiadi E. Ndumele, Justin B. Echouffo-Tcheugui, Rita R. Kalyani, Wendy L. Bennett, Erin D. Michos

Erschienen in: Current Diabetes Reports | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cardiovascular disease (CVD) complications constitute about 50–70% of mortality in people with diabetes. However, there remains a persistently greater relative increase in CVD morbidity and mortality in women with diabetes than in their male counterparts. This review presents recent evidence for the risks, outcomes, and management implications for women with diabetes.

Recent Findings

Compared to men, women have higher BMI and more adverse cardiovascular risk profile at time of diabetes diagnosis with greater risk for coronary heart disease, stroke, vascular dementia, and heart failure. Pregnancy-specific risk factors of gestational diabetes and pre-eclampsia are associated with future type 2 diabetes (T2D) and CVD. Women with T2D may experience greater benefits than men from GLP-1 receptor agonists.

Summary

Women with diabetes are at greater relative risk for CVD complications than men, with poorer outcomes, superimposed on preexisting gender disparities in social determinants of health, lower likelihood of being offered cardioprotective interventions, and enrollment in trials. Further research and the utilization of SGLT-2 inhibitors, GLP-1 receptor agonists, and other CVD prevention strategies will help reduce morbidity and mortality.
Literatur
1.
Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143:e254–743.PubMedCrossRef
2.
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.PubMedCrossRef
3.
Taponen S, Martikainen H, Järvelin MR, et al. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab. 2004;89:2114–8.PubMedCrossRef
4.••
Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999–2018. N Engl J Med 2021;384:2219–2228. This recent study demonstrated that diabetes control has worsened since 2010 among a representative sample of U.S. adults, for both women and men.
5.
American Diabetes Association. Chapter 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S15-S33.
6.
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83.PubMedPubMedCentralCrossRef
7.
Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167:1145–51.PubMedCrossRef
8.
Recarti C, Sep SJ, Stehouwer CD, Unger T. Excess cardiovascular risk in diabetic women: a case for intensive treatment. Curr Hypertens Rep. 2015;17:554.PubMedCrossRef
9.
10.••
Prospective Studies Collaboration, Asia Pacific Cohort Studies Collaboration. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol 2018;6:538–546. A large meta-analysis of over 980,000 adults, which showed diabetes was associated with a 2-fold increased risk of vascular mortality in men but a 3-fold risk in women, with a significant interaction by sex p<0.0001.
11.
Angoulvant D, Ducluzeau PH, Renoult-Pierre P, et al. Impact of gender on relative rates of cardiovascular events in patients with diabetes. Diabetes Metab. 2021;47:101226.PubMedCrossRef
12.
Huxley RR, Peters SA, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:198–206.PubMedCrossRef
13.
14.
Williams JS, Egede LE. Differences in medical expenditures for men and women with diabetes in the medical expenditure panel survey, 2008–2016. Womens Health Rep. 2020;1:345–53.
15.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018;41:917–928.
16.
Dall TM, Yang W, Gillespie K, et al. The economic burden of elevated blood glucose levels in 2017: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care. 2019;42:1661–8.PubMedPubMedCentralCrossRef
17.
Williams JS, Bishu K, Dismuke CE, Egede LE. Sex differences in healthcare expenditures among adults with diabetes: evidence from the medical expenditure panel survey, 2002–2011. BMC Health Serv Res. 2017;17:259.PubMedPubMedCentralCrossRef
18.••
Al-Salameh A, Chanson P, Bucher S, Ringa V, Becquemont L. Cardiovascular disease in type 2 diabetes: a review of sex-related differences in predisposition and prevention. Mayo Clinic Proc 2019;94:287–308. This meta-analysis demonstrates the higher adverse CVD outcomes in women in diabetes compared to men.
19.
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383:999–1008.PubMedCrossRef
20.
Chatterjee S, Peters SA, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39:300–7.PubMedCrossRef
21.••
Segar MW, Khan MS, Patel KV et al. Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults. J Am Coll Cardiol 2021;78:1587–1598. This recent pooled cohort study showed that the prevalence of diabetic cardiomyopathy (by imaging and biomarkers) is common, ranging from 12 to 67% depending on the definition, and is associated with significant increased risk of future heart failure.
22.••
Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia 2019;62:1550–1560. A large meta-analysis including 47 cohorts and over 12 million individuals showed that the excess risk of heart failure conferred by diabetes was greater in women than in men.
23••.
Dennison RA, Chen ES, Green ME et al. The absolute and relative risk of type 2 diabetes after gestational diabetes: a systematic review and meta-analysis of 129 studies. Diabetes Res Clin Pract 2021;171:108625. This meta-analysis provides evidence that women with GDM have an 8.3-fold relative risk of T2D from 6 months postpartum.
24.••
Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia 2019;62:905–914. This study provides evidence that women with GDM have 50% risk of developing T2D and other adverse cardiovascular events up to a decade postpartum.
25.•
Echouffo-Tcheugui JB, Guan J, Retnakaran R, Shah BR. Gestational Diabetes and Incident Heart Failure: A Cohort Study. Diabetes Care 2021;dc210552. Online ahed of print. This large population-based study showed that women with GDM had increased risk of developing incident heart failure, even after adjusting for postpartum diabetes and other risk factors. GDM was associated with increased risk of peripartum cardiomyopathy as well.
26.••
Gunderson EP, Sun B, Catov JM et al. Gestational diabetes history and glucose tolerance after pregnancy associated with coronary artery calcium in women during midlife: the CARDIA study. Circulation 2021;143:974–987. Compared to women without history of GDM, there is a 2-fold higher risk of CAC in women with history of GDM, with risk persistence after returning to normoglycemia.
27.•
Elkind-Hirsch KE, Seidemann E, Harris R. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. Am J Obstet Gynecol MFM 2020;2:100139. Postpartum treatment with combined dapagliflozin-metformin showed superiority to metformin monotherapy in improving metabolic status (weight loss and reduced central adiposity) in obese women with prior GDM.
28.•
Elkind-Hirsch KE, Shaler D, Harris R. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: a double-blind, randomized, placebo-controlled study. J Diabetes Complications 2020;34:107548. Results of this clinical trial demonstrate postpartum treatment with combined liraglutide-metformin showed superiority to metformin monotherapy in improving metabolic status (weight loss and reduced central adiposity) in obese women with prior GDM.
29.•
Yoshida Y, Chen Z, Baudier RL et al. Early menopause and cardiovascular disease risk in women with or without type 2 diabetes: a pooled analysis of 9,374 postmenopausal women. Diabetes Care 2021.;dc211107. Online ahead of print.This pooled analysis found that the CV risk associated with early menopause was greater among women with T2D than those without T2D.
30.•
Wong ND, Cordola Hsu AR, Rozanski A et al. Sex differences in coronary artery calcium and mortality from coronary heart disease, cardiovascular disease, and all causes in adults with diabetes: the Coronary Calcium Consortium. Diabetes Care 2020;43:2597–2606. This study showed that among patients with diabetes, the risks of all-cause and CV mortality associated with an elevated CAC score were greater among women compared to men, with significant interaction by sex.
31.
Ferrannini G, Maldonado JM, Raha S, et al. Gender differences in cardiovascular risk, treatment, and outcomes: a post-hoc analysis from the REWIND trial. EASD Abstract 5. 57thEASD Annual Meeting of the European Association for the Study of Diabetes. Diabetologia. 2021;64:1–380.
32.
Cifkova R, Pitha J, Krajcoviechova A, Kralikova E. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. Int J Cardiol. 2019;286:214–9.
33.
Toedebusch R, Belenchia A, Pulakat L. Diabetic Cardiomyopathy: impact of Biological Sex on Disease Development and Molecular Signatures. Front Physiol. 2018;9:453.PubMedPubMedCentralCrossRef
34.
Kim HL, Kim MA, Park KT, et al. Gender difference in the impact of coexisting diabetes mellitus on long-term clinical outcome in people with heart failure: a report from the Korean Heart Failure Registry. Diabet Med. 2019;36:1312–8.PubMedCrossRef
35.
Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360. Hyattsville, MD: National Center for Health Statistics. 2020.
36.
Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32:1431–7.CrossRef
37.
Peters SAE, Muntner P, Woodward M. Sex differences in the prevalence of, and trends in, cardiovascular risk factors, treatment, and control in the United States, 2001 to 2016. Circulation. 2019;139:1025–35.PubMedCrossRef
38.
Bancks MP, Kershaw K, Carson AP, Gordon-Larsen P, Schreiner PJ, Carnethon MR. Association of modifiable risk factors in young adulthood with racial disparity in incident type 2 diabetes during middle adulthood. JAMA. 2017;318:2457–65.PubMedPubMedCentralCrossRef
39.
Huebschmann AG, Huxley RR, Kohrt WM, Zeitler P, Regensteiner JG, Reusch JEB. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia. 2019;62:1761–72.PubMedPubMedCentralCrossRef
40.
Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses’ Health Study. Am J Epidemiol. 1997;145:614–9.PubMedCrossRef
41.
Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481–6.PubMedCrossRef
42.
Paul S, Thomas G, Majeed A, Khunti K, Klein K. Women develop type 2 diabetes at a higher body mass index than men. Diabetologia. 2012;55:1556–7.PubMedCrossRef
43.
Regensteiner JG, Golden S, Huebschmann AG, et al. Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2015;132:2424–47.PubMedCrossRef
44.
Nordstrom A, Hadrevi J, Olsson T, Franks PW, Nordstrom P. Higher prevalence of type 2 diabetes in men than in women is associated with differences in visceral fat mass. J Clin Endocrinol Metab. 2016;101:3740–6.PubMedCrossRef
45.
46.
Jonsdottir LS, Sigfusson N, Gudnason V, Sigvaldason H, Thorgeirsson G. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study J Cardiovasc Risk. 2002;9:67–76.PubMedCrossRef
47.
Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, Ferrannini E. Hypertension and diabetes mellitus: coprediction and time trajectories. Hypertension. 2018;71:422–8.PubMedCrossRef
48.
Juutilainen A, Kortelainen S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care. 2004;27:2898–904.PubMedCrossRef
49.
de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:1273–84.PubMedCrossRef
50.
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150–9.PubMed
51.
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74:1376–414.PubMedPubMedCentralCrossRef
52.
Chodick G, Tenne Y, Barer Y, Shalev V, Elchalal U. Gestational diabetes and long-term risk for dyslipidemia: a population-based historical cohort study. BMJ Open Diabetes Research and Care. 2020;8(1):e000870.
53.
Lai M, Al Rijjal D, Röst HL, Dai FF, Gunderson EP, Wheeler MB. Underlying dyslipidemia postpartum in women with a recent GDM pregnancy who develop type 2 diabetes. Elife. 2020;9:e59153. 
54.
Nasioudis D, Doulaveris G, Kanninen TT. Dyslipidemia in pregnancy and maternal-fetal outcome. Minerva Ginecol. 2019;71:155–62.PubMedCrossRef
55.
Burke GM, Genuardi M, Shappell H, D’Agostino RB Sr, Magnani JW. Temporal associations between smoking and cardiovascular disease, 1971 to 2006 (from the Framingham Heart Study). Am J Cardiol. 2017;120:1787–91.PubMedPubMedCentralCrossRef
56.
Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378:1297–305.PubMedCrossRef
57.
Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke. 2013;44:2821–8.PubMedCrossRef
58.
Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. 1998;316:1043–7.PubMedPubMedCentralCrossRef
59.
Al-Delaimy WK, Willett WC, Manson JE, Speizer FE, Hu FB. Smoking and mortality among women with type 2 diabetes: the Nurses’ Health Study cohort. Diabetes Care. 2001;24:2043–8.PubMedCrossRef
60.
61.
Benowitz NL, Burbank AD. Cardiovascular toxicity of nicotine: implications for electronic cigarette use. Trends Cardiovasc Med. 2016;26:515–23.PubMedPubMedCentralCrossRef
62.
Mansfield MW, Heywood DM, Grant PJ. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16:160–4.PubMedCrossRef
63.
Alzahrani SH, Hess K, Price JF, et al. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab. 2012;97:E2282–7.PubMedCrossRef
64.
Elder P, Sharma G, Gulati M, Michos ED. Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention. Am J Prev Cardiol. 2020;2:100028.PubMedPubMedCentralCrossRef
65.
Okoth K, Chandan JS, Marshall T, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ. 2020;371:m3502.PubMedPubMedCentralCrossRef
66.
Zhao G, Bhatia D, Jung F, Lipscombe L. Risk of type 2 diabetes mellitus in women with prior hypertensive disorders of pregnancy: a systematic review and meta-analysis. Diabetologia. 2021;64:491–503.PubMedCrossRef
67.
Minhas AS, Ogunwole SM, Vaught AJ, et al. Racial disparities in cardiovascular complications with pregnancy-induced hypertension in the United States. Hypertension. 2021;78:480–8.PubMedCrossRef
68.
Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer AA, Kadam U, Chew-Graham CA, Mamas MA. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circulation: Cardiovascular Quality and Outcomes. 2017;10(2):e003497.
69.
70.
71.
Wu P, Kwok CS, Haththotuwa R, et al. Pre-eclampsia is associated with a twofold increase in diabetes: a systematic review and meta-analysis. Diabetologia. 2016;59:2518–26.PubMedPubMedCentralCrossRef
72.
World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. World Health Organization; 2013. 
73.
Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.PubMedCrossRef
74.
Wagan N, Amanullah AT, Makhijani PB, Kumari R. Factors associated with gestational diabetes mellitus: a cross-sectional study. Cureus. 2021;13:e17113.PubMedPubMedCentral
75.
De Souza LR, Berger H, Retnakaran R, et al. First-trimester maternal abdominal adiposity predicts dysglycemia and gestational diabetes mellitus in midpregnancy. Diabetes Care. 2016;39:61–4.PubMedCrossRef
76.
Damm P, Houshmand-Oeregaard A, Kelstrup L, Lauenborg J, Mathiesen ER, Clausen TD. Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark. Diabetologia. 2016;59:1396–9.PubMedCrossRef
77.
Johns EC, Denison FC, Norman JE, Reynolds RM. Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab. 2018;29:743–54.PubMedCrossRef
78.
Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11):3342.
79.
Aroda VR, Christophi CA, Edelstein SL, et al. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab. 2015;100:1646–53.PubMedPubMedCentralCrossRef
80.
Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30:399–404.PubMedCrossRef
81.
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet Gynecol 2018;131:e157-e171.
82.
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31:2841–55.PubMedCrossRef
83.
Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol. 2018;17:37.PubMedPubMedCentralCrossRef
84.
Oliver-Williams C, Vassard D, Pinborg A, Schmidt L. Risk of cardiovascular disease for women with polycystic ovary syndrome: results from a national Danish registry cohort study. European Journal of Preventive Cardiology. 2021;28(12):e39–41.
85.
DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454–60.PubMedCrossRef
86.
Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome–a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92:4546–56.PubMedCrossRef
87.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800.PubMed
88.
Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12:324–32.PubMedCrossRef
89.
Joham AE, Ranasinha S, Zoungas S, Moran L, Teede HJ. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99:E447–52.PubMedCrossRef
90.
Lunde O, Tanbo T. Polycystic ovary syndrome: a follow-up study on diabetes mellitus, cardiovascular disease and malignancy 15–25 years after ovarian wedge resection. Gynecol Endocrinol. 2007;23:704–9.PubMedCrossRef
91.
Wang ET, Calderon-Margalit R, Cedars MI, et al. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol. 2011;117:6–13.PubMedPubMedCentralCrossRef
92.
Paschou SA, Anagnostis P, Goulis DG, Lambrinoudaki I. Androgen excess and post-reproductive health. Maturitas. 2018;115:115–6.PubMedCrossRef
93.
Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause (New York, NY). 2012;19:1081–7.CrossRef
94.
Peters SA, Woodward M. Women’s reproductive factors and incident cardiovascular disease in the UK Biobank. Heart. 2018;104:1069–75.PubMedCrossRef
95.
Honigberg MC, Zekavat SM, Aragam K, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322:2411–21.PubMedPubMedCentralCrossRef
96.
LeBlanc ES, Kapphahn K, Hedlin H, et al. Reproductive history and risk of type 2 diabetes mellitus in postmenopausal women: findings from the Women’s Health Initiative. Menopause. 2017;24:64–72.PubMedPubMedCentralCrossRef
97.
Muka T, Asllanaj E, Avazverdi N, et al. Age at natural menopause and risk of type 2 diabetes: a prospective cohort study. Diabetologia. 2017;60:1951–60.PubMedPubMedCentralCrossRef
98.
Aroda VR, Taub PR, Stanton A-M. Diabetes with cardiomyopathy. J Am Coll Cardiol. 2021;78:1599–602.PubMedCrossRef
99.
Michos ED, Blaha MJ, Blumenthal RS. Use of the coronary artery calcium score in discussion of initiation of statin therapy in primary prevention. Mayo Clinic Proc. 2017;92:1831–41.CrossRef
100.
Minhas A, Cubero Salazar I, Kazzi B, et al. Sex-specific plaque signature: uniqueness of atherosclerosis in women. Curr Cardiol Rep. 2021;23:84.PubMedCrossRef
101.
Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800–11.PubMedPubMedCentralCrossRef
102.
Suneja S, Gangopadhyay S, Saini V, Dawar R, Kaur C. Emerging Diabetic Novel Biomarkers of the 21st Century. Annals of the National Academy of Medical Sciences (India). 2021.
103.
Wittenbecher C, Stambuk T, Kuxhaus O, et al. Plasma N-glycans as emerging biomarkers of cardiometabolic risk: a prospective investigation in the EPIC-Potsdam Cohort Study. Diabetes Care. 2020;43:661–8.PubMedCrossRef
104.
Bogdanet D, Reddin C, Murphy D, Doheny HC, Halperin JA, Dunne F, O’Shea PM. Emerging Protein Biomarkers for the Diagnosis or Prediction of Gestational Diabetes—A Scoping Review. Journal of Clinical Medicine. 2021;10(7):1533. 
105.
Wright AK, Kontopantelis E, Emsley R, et al. Cardiovascular risk and risk factor management in type 2 diabetes mellitus. Circulation. 2019;139:2742–53.PubMedCrossRef
106.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRef
107.
Franzini L, Ardigo D, Cavalot F, et al. Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND. IT Study Group of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis. 2013;23:235–41.PubMedCrossRef
108.
Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572–82.PubMedCrossRef
109.
Billimek J, Malik S, Sorkin DH, et al. Understanding disparities in lipid management among patients with type 2 diabetes: gender differences in medication nonadherence after treatment intensification. Womens Health Issues. 2015;25:6–12.PubMedCrossRef
110.
Kautzky-Willer A, Kamyar MR, Gerhat D, et al. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. Gend Med. 2010;7:571–83.PubMedCrossRef
111.
Baviera M, Santalucia P, Cortesi L, et al. Sex differences in cardiovascular outcomes, pharmacological treatments and indicators of care in patients with newly diagnosed diabetes: analyses on administrative database. Eur J Intern Med. 2014;25:270–5.PubMedCrossRef
112.
Cho L, Davis M, Elgendy I, et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2602–18.PubMedPubMedCentralCrossRef
113.
Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010;87:211–8.PubMedCrossRef
114.
ASCEND Collaborative Group, Bowman L, Mafham M et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:1529–1539.
115.
Radholm K, Zhou Z, Clemens K, Neal B, Woodward M. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab. 2020;22:263–6.PubMedCrossRef
116.
Singh AK, Singh R. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials. Diabetes Metab Syndr. 2020;14:181–7.PubMedCrossRef
117.
Clemens KK, Woodward M, Neal B, Zinman B. Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis. Diabetes Care. 2020;43:1157–63.PubMedCrossRef
118.
Khan MS, Shahid I, Siddiqi TJ, et al. Ten-year trends in enrollment of women and minorities in pivotal trials supporting recent US Food and Drug Administration approval of novel cardiometabolic drugs. J Am Heart Assoc. 2020;9:e015594.PubMedPubMedCentralCrossRef
119.
Wenger NK. Clinical presentation of CAD and myocardial ischemia in women. J Nucl Cardiol. 2016;23:976–85.PubMedCrossRef
120.
Leifheit-Limson EC, D’Onofrio G, Daneshvar M, et al. Sex differences in cardiac risk factors, perceived risk, and health care provider discussion of risk and risk modification among young patients with acute myocardial infarction: the VIRGO study. J Am Coll Cardiol. 2015;66:1949–57.PubMedPubMedCentralCrossRef
121.
Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA. 2000;283:3223–9.PubMedCrossRef
122.
Wei J, Mehta PK, Grey E, et al. Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol. Am Heart J. 2017;191:30–6.PubMedPubMedCentralCrossRef
123.
Metadaten
Titel
The Diabetes-Cardiovascular Connection in Women: Understanding the Known Risks, Outcomes, and Implications for Care
verfasst von
Eric K. Broni
Chiadi E. Ndumele
Justin B. Echouffo-Tcheugui
Rita R. Kalyani
Wendy L. Bennett
Erin D. Michos
Publikationsdatum
14.02.2022
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 1/2022
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-021-01444-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise